Intellia Therapeutics (NTLA) Return on Equity (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Quarterly Return on Equity changed 0.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
• Return on Equity eased to 0.01% in Q1 2026 per NTLA's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q1 2023 and bottomed at 0.01% in Q2 2025.
• The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.0%.
• Peak annual rise in Return on Equity reached 0 bps in 2022, while the deepest fall reached 0 bps in 2022.
• Tracing NTLA's Return on Equity over 5 years: stood at 0.0% in 2022, then retreated by 2 bps to 0.0% in 2023, then declined by 19 bps to 0.01% in 2024, then slipped by 9 bps to 0.01% in 2025, then fell by 5 bps to 0.01% in 2026.
• Per Business Quant, the three latest NTLA Return on Equity figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).

Peer Comparison